Pharmadrug Inc. (LMLLF)
Pharmadrug Inc. operates as a specialized pharmaceutical company, primarily dedicated to the exploration, development, and commercialization of controlled substances and naturally derived therapeutic agents. Its portfolio encompasses novel compounds like psychedelics and cannabis, alongside other naturally sourced approved medicines. Beyond its core research and development activities, the firm plays a crucial role in importing and distributing medical cannabis to pharmacies across Germany and the broader European Union. The company also oversees Super Smart, an initiative focused on promoting and exploring the benefits of functional and psilocybin mushrooms. Additionally, Pharmadrug actively engages in researching and enhancing established natural remedies. Significant research collaborations underpin its innovative pipeline, including an agreement with the University of Michigan to assess N, N-dimethyltryptamine's (DMT) role in various conscious states. Another partnership with the Southwest Research Institute is geared towards the non-clinical and clinical manufacturing of cepharanthine. Furthermore, a clinical trial agreement with Johns Hopkins University facilitates a study comparing the acute and enduring psychological and neural effects of DMT against an undisclosed, highly active comparator molecule. Headquartered in Toronto, Canada, the company adopted its current name, Pharmadrug Inc., in October 2019, having previously operated as Aura Health Inc.
Sector: Drug Manufacturers - Specialty & Generic
Industry: Drug Manufacturers - Specialty & Generic
Pharmadrug Inc.
- 0.0%
- 33.7K
- 51.86
Float 132.83M · FMP free float
The cost to borrow LMLLF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 100.0%
- 654
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 33.7K sh |
| Oct 15, 2026 | 33.7K sh |
| Sep 30, 2026 | 33.7K sh |
| Sep 15, 2026 | 37.0K sh |
| Aug 31, 2026 | 37.0K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Sep 22, 2026 | 654 sh |
| Aug 10, 2026 | 4.4K sh |
| Aug 7, 2026 | 4.4K sh |
| Aug 5, 2026 | 4.4K sh |
| Aug 4, 2026 | 4.4K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 11, 2026 | 100.0% |
| Oct 27, 2026 | 32.2% |
| Oct 9, 2026 | 100.0% |
| Sep 21, 2026 | 100.0% |
| Aug 28, 2026 | 100.0% |
130 calendar days requested; 14 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for LMLLF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 33,711 LMLLF shares were sold short (0.03% of a 132.83M-share float, 51.86 days to cover).